India Digital Therapeutics Market Outlook to 2030

India Digital Therapeutics Market Overview

• In 2023, the India digital therapeutics (DTx) market was valued at USD 178 million. The market's growth is driven by the rising prevalence of chronic diseases like diabetes, cardiovascular issues, and respiratory disorders, which require ongoing digital management solutions. The increasing adoption of smartphones and enhanced internet penetration, particularly in rural regions, is also pushing the market forward. India's significant healthcare burden, combined with technological innovations, provides the market with an opportunity for sustainable growth.

• Several key players are driving the India DTx market. Prominent companies include Wellthy Therapeutics, BeatO, and Fitterfly, which offer digital platforms addressing diabetes and hypertension management. International companies like Livongo (now part of Teladoc) and Omada Health are also expanding their reach in India. These players are collaborating with healthcare providers and leveraging AI-based platforms to offer personalized health solutions, contributing to the markets expansion.
• The India DTx market is dominated by metropolitan areas such as Mumbai, Delhi, and Bengaluru. These cities are hubs for digital health startups, healthcare institutions, and advanced technological infrastructure. Additionally, high awareness levels, better healthcare access, and a higher rate of smartphone usage contribute to the dominance of these cities. Mumbai, for example, houses multiple leading digital therapeutics companies, ensuring the citys continued dominance in this sector through its robust digital health ecosystem.
• In 2023, the Indian government launched the Digital Health Mission under the Ayushman Bharat scheme, focusing on promoting digital healthcare solutions, including DTx, across the country. This initiative aims to create a National Digital Health Ecosystem by 2024, offering integrated and accessible healthcare data to millions. The government's support for digitizing healthcare, combined with policy reforms, is catalyzing the adoption of digital therapeutics platforms, which are viewed as a crucial element in the future of healthcare in India.

India Digital Therapeutics Market Segmentation

• By Disease Type: The market is segmented by disease type into diabetes, cardiovascular diseases, and obesity. In 2023, diabetes management held the dominant market share. This is due to the increasing prevalence of diabetes in India, with over 77 million patients as of 2023. Solutions like those from BeatO and Wellthy Therapeutics focus on managing glucose levels, lifestyle changes, and medication adherence. As diabetes requires constant monitoring, digital tools provide an accessible way for patients to manage their condition remotely, contributing to the dominance of this segment.

• By Product Type: The market is segmented by product type into software-based platforms, hardware-based devices, and standalone mobile apps. Software-based platforms dominated the market in 2023, as these platforms offer a holistic approach to healthcare management. Many software platforms integrate multiple chronic disease management tools into a single platform, offering a seamless experience for users. These platforms often use AI to provide personalized care plans, monitor patient data, and offer real-time insights. Their ease of use and integration with other healthcare systems has made them a popular choice among users.

• By Region: The India digital therapeutics market is segmented by region into North, South, East and West. In 2023, Western region held the largest market share due to the regions higher concentration of healthcare institutions and technology companies. The presence of advanced IT infrastructure, especially in Maharashtra, and the adoption of digital healthcare solutions in the region contribute to its dominance. Additionally, major players in digital health are headquartered here, driving regional growth. West India also benefits from a strong investment ecosystem, which supports digital health startups.

India Digital Therapeutics Market Competitive Landscape

• Wellthy Therapeutics: In August 2023, Wellthy Therapeutics expanded its strategic collaboration with Lupin to further extend their digital diabetes care solutions across India. The platform aims to reach over 1 million patients in the next two years. Wellthy Therapeutics has invested in AI-based technologies to provide real-time insights to patients and healthcare professionals, helping reduce complications and improve outcomes.
• BeatO: BeatO, a Delhi-based digital health platform, secured INR 55 crore in funding in July 2023. The company aims to use the funds to expand its diabetes care offerings across tier-2 and tier-3 cities. The platform, which combines smartphone-enabled glucometers with a comprehensive diabetes management app, now serves over 1 million users, marking a significant milestone for its mission to make chronic disease management accessible.

India Digital Therapeutics Market Analysis

Growth Drivers

• Rising Prevalence of Chronic Diseases: One of the significant growth drivers of the India Digital Therapeutics (DTx) market is the increasing burden of chronic diseases. As per a 2023 report by the Indian Council of Medical Research (ICMR), India has more than 77 million people diagnosed with diabetes, making it the second-highest in the world. Additionally, the World Health Organization (WHO) estimates that cardiovascular diseases account for nearly 28% of all deaths in India annually. This growing burden of chronic diseases is driving the adoption of digital therapeutics as a scalable solution for disease management, contributing to the increasing demand for DTx platforms in 2024.
• Government's Push Towards Digital Healthcare: The Indian governments initiatives towards building a robust digital health infrastructure are pivotal in driving the growth of the DTx market. In 2022, the government launched the Ayushman Bharat Digital Mission (ABDM) as part of the National Digital Health Mission (NDHM). The mission aims to digitize health records of millions of Indian citizens by 2025, creating a connected ecosystem of digital health services. In 2024, the program reported onboarding over 200 million citizens, improving access to digital therapeutics by enabling the integration of digital platforms within mainstream healthcare.
• Growing Smartphone Penetration and Internet Access: India's expanding digital infrastructure, coupled with increasing smartphone usage, is another key growth driver for the DTx market. According to the Telecom Regulatory Authority of India (TRAI), India had over 850 million internet users by the end of 2023, with rural areas accounting for a significant portion of new internet connections. This widespread internet access is critical for the digital therapeutics market, allowing patients in both urban and rural areas to access remote healthcare services.

Challenges

• Limited Awareness Among Healthcare Providers: Despite the rising demand for digital therapeutics, one of the main challenges for the India DTx market is the limited awareness among healthcare professionals. This gap in knowledge leads to resistance among physicians when recommending or prescribing digital therapeutics. In 2024, addressing this knowledge gap through awareness programs and medical training will be essential to increasing the adoption rate of DTx solutions in clinical practice, as only well-informed healthcare professionals can encourage widespread use among patients.
• Data Privacy and Security Concerns: With the increased usage of digital health platforms, there has been a rise in apprehensions about the security of patient data. In 2023, India introduced the Digital Personal Data Protection Act to regulate the collection, processing, and storage of digital health data. However, the lack of stringent enforcement mechanisms poses challenges for companies in securing sensitive health information, leading to reluctance among patients and healthcare providers.

Government Initiatives

1. Ayushman Bharat Digital Mission (ABDM) 2022
   Launched in September 2022, the Ayushman Bharat Digital Mission (ABDM) aims to digitize the healthcare ecosystem of India by creating a secure and integrated digital health infrastructure. In 2024, over 200 million health records had been digitized under the scheme, allowing patients and healthcare providers to access health data through a unified digital platform. The initiative's push towards digital health integration supports the growth of digital therapeutics by enabling seamless access to digital tools for chronic disease management, thus promoting patient engagement with DTx platforms.
2. National Digital Health Mission (NDHM) 2021
   The National Digital Health Mission (NDHM), launched in 2021, focuses on establishing a robust digital health ecosystem by linking healthcare stakeholders through technology. By 2024, the initiative had reached over 500 million individuals with a digital health ID, streamlining the delivery of digital therapeutics solutions. This initiative has been instrumental in creating a framework for digital healthcare delivery in India, including digital therapeutics, which is gaining popularity as patients seek more convenient and personalized care options.

India Digital Therapeutics Market Future Outlook

Over the next five years, the India Digital Therapeutics (DTx) market is projected to experience robust growth, driven by advancements in technology, government initiatives, and increasing patient demand for personalized healthcare solutions. The market is expected to be deeply integrated with the broader healthcare ecosystem, offering enhanced digital health solutions for managing chronic diseases like diabetes, cardiovascular issues, and obesity. A significant factor contributing to this growth will be the increased focus on AI and machine learning technologies, enabling DTx platforms to offer highly tailored treatment plans and real-time monitoring for patients.

Future Trends

• Expansion of AI-Powered DTx Platforms: Artificial intelligence will play a pivotal role in the future of digital therapeutics in India. AI-powered platforms will dominate the market, offering personalized care plans, remote monitoring, and real-time analysis of patient data. These platforms will not only improve patient outcomes but will also significantly reduce the burden on healthcare providers, making them a cornerstone of chronic disease management.
• Integration with Health Insurance Providers: Digital therapeutics platforms will become a regular feature in health insurance packages, offering preventive care solutions as part of health policies. Insurance companies will increasingly collaborate with DTx providers to offer policyholders tools for managing chronic diseases, reducing healthcare costs, and improving overall patient health outcomes.